The Dietary Supplement and Prescription Medication Section (DSQ) of the Sample Person (SP) Questionnaire, collects information on 1) dietary supplements, 2) nonprescription antacids, 3) prescription medications, and 4) asthma medications.
The Prescription Medication subsection provides personal interview data on use of prescription medications during a one-month period prior to the survey date. The NHANES 2007–2008 prescription medication questions are similar to the NHANES 1999–2006 and NHANES III, 1988–1994 questions.
All survey participants are eligible for the prescription medication questions.
The Prescription Medication questionnaire was done before the physical examination, in the home, using the Computer-Assisted Personal Interviewing-CAPI (interviewer-administered) system. Participants over 16 years of age answered for themselves; A proxy provided information for survey participants who were under 16 years of age and for individuals who could not answer the questions themselves.
The Interviewer Procedure Manuals and Survey Questionnaires can be found on the NHANES website.
Data were routinely examined for discrepancies and erroneous entries. All drug names entered by the interviewer were compared to the medication name selected from the database. Review of the 2007–2008 data found that 92% of all reported drugs were automatically matched to the data collection drug database. The 8%, which were not matched to the drug database, were edited after data collection at NCHS. The most common reasons for a non-match were incorrect spelling of the drug, insufficient detail to identify the drug, and reporting of a nonprescription product that was not in the drug database. Details of the editing process are described below.
Data Collection Methods
During the household interview survey participants are asked if they have taken medications in the past month for which they needed a prescription. Those who answer “yes” are asked to show the interviewer the medication containers of all the products used. For each medication reported, the interviewer enters the product’s complete name from the container into a computer. If no container is available, the interviewer asks the participant to verbally report the name of the medication.
When the interviewer enters the medication name into the computer, the name is automatically matched to a prescription drug database on the computer to identify an exact match or similar text matches (refer below for details on the prescription medication database). The interviewer then selects the best match from a list of possible matches. The original entry of the interviewer and the product selected from the computer list are saved under separate variables for quality control purposes. If an exact match of the medication cannot be found, the interviewer is instructed to select “drug not found on list” from the list. Interviewers can record up to 20 prescription medications.
Participants are also asked how long they had been taking the medication and the main reason for use.
The NHANES 2007–2008 prescription medication questions can be accessed in the Dietary Supplements and Prescription Medications Section of the Sample Person Questionnaire.
Prescription Medication Questions Included in this Data Release
Prescription Medication Database for Data Collection
NCHS used the Lexicon Plus®, a proprietary database of Cerner Multum, Inc. to assist in data collection. The Lexicon Plus® is a comprehensive database of all prescription and some nonprescription drug products available in the U.S. drug market. For NHANES, the Lexicon Plus® files were modified and uploaded to a laptop computer and incorporated into a search engine for use by interviewers in the field. The computer file is updated at the beginning of each survey year to incorporate changes to the Lexicon Plus® and include products approved and available to the U.S. public in the prior year.
Data Editing
General editing of data:
When a variable was modified globally, as part of the editing process, the third letter in the variable name was changed from a Q (i.e. RXQ) to a D (i.e. RXD). For example, variables that were obtained from an external drug database will have the letter "D" in the third position of the variable name.
Prescription medications incorrectly reported in subsections of questionnaire:
Prescription antacids that were incorrectly reported in the nonprescription antacid section of the questionnaire were removed from the antacid file and added to the prescription medication file.
Prescription supplements are released in the Dietary Supplements Data File. Some prescription medications were mistakenly recorded in the dietary supplement section. These were removed from that file and added to the prescription medication file. Any prescription dietary supplement that was incorrectly reported in the prescription medication section was removed from the prescription medication section and moved to the dietary supplement section. The following products were moved to the dietary supplements files:
All prescription niacin, potassium, and sodium products were retained in the prescription medication file.
Products reported in the prescription medication section that were only available as an over-the-counter product during 2007–2008 were removed from the prescription medication file, except over-the-counter insulin isophane, insulin regular, and products containing pseudoephedrine.
Specific variables and edits:
RXDUSE: Have you taken or used any prescription medicines in the past month?
This variable was the lead-in question to the series of questions on prescription medication use. It accounts for all prescription medications except prescription dietary supplements that are included in the dietary supplement files (DSQ). A small number of persons refused to answer this question (coded 7) or did not know whether they used a prescription medication in the past month (coded 9).
This variable was edited and takes into account prescription medications reported in this section as well as prescription medications moved in from the dietary supplements or nonprescription antacids of the questionnaire.
RXDCOUNT: The number of prescription medicines taken
This variable was computed at NCHS and represents the total number of prescription medications reported by the respondent, including those drugs identified as unknown (RXDDRUG = 55555). The count has been adjusted for all prescription medications moved into and those moved out of the prescription medication section. However, the count is not a comprehensive count of all prescription medications used by a participant because prescription dietary supplements are part of the dietary supplement section. There were also participants who reported the use of a prescription medication in the past month (RXDUSE = 1) but did not know the name of the medication (RXDDRUG = 99999) or refused to report the name of the medication (RXDDRUG = 77777). Each product reported as refused or don’t know is still included in the total count of prescription medications used under RXDCOUNT.
RXQSEEN: Medicine container seen by interviewer?
There was no editing of this variable.
RXDDAYS: For how long have you been taking this medicine?
This variable was created from a two-part (number and unit) question and indicates how long the respondent reported taking each prescription medication. Responses were recorded in days, weeks, months, and years. To facilitate analysis, all answers were converted to days using conversion factors of 7 days per week, 30.4 days per month, and 365 days per year. There were persons who reported the use of a prescription medication but did not know how long they had been using the medication (RXDDAYS = 99999) or refused to report the length of use (RXDDAYS = 77777). There were also persons who reported the use of a prescription medication but did not report the length of use. RXDDAYS is missing for these persons.
Drug Database for Data Release:
NCHS used the Lexicon Plus®, a proprietary database of Cerner Multum, Inc. to assist with data editing and release. For additional information refer to the RXQ_DRUG documentation.
In accordance with the license agreement, NCHS publications, tabulations, and software applications should cite the Multum Lexicon as the source and basis for the coding and classification of the NHANES drug data.
Creation of additional data release variables:
RXDDRUG: Generic drug name
All reported drug names were converted to a standard generic drug name for data release. For multi-ingredient products, the ingredients are listed in alphabetical order (i.e., Acetaminophen; Codeine).
There were participants who reported the use of a prescription medication but did not know the name of the drug or refused to report the name. These entries were coded as don’t know (99999) and refused (77777), respectively. There were also medications reported with insufficient detail to accurately identify the exact product, but there was some information about the therapeutic class of the drug. These products have been released with Multum’s therapeutic category name followed by “- unspecified” (e.g., anti-infective-unspecified, hormones-unspecified). The names of a limited number of reported drugs could not be identified by NCHS as a known prescription product. These entries are counted as prescription medications, since there is no evidence that they are not, and have been coded as 55555, unknown drug.
RXDDRGID: Generic drug code
Each generic drug name is associated with a unique generic drug code from Multum’s Lexicon Drug Database. There were some drug names reported by NHANES’ participants that were not found in the Lexicon Drug Database. These have been assigned unique drug codes beginning with an “a” or “h”. Unspecified products with known therapeutic action have drug codes beginning with a “c” and are followed by their respective Multum therapeutic category code. RXDDRGID is missing for unknown drugs (55555), refused (77777), or don’t know (99999) RXDDRUG entries.
Therapeutic class codes associated with a drug are found in a separate data release file, RXQ_DRUG.
There are two files related to the prescription drug data. The contents of each file are described below. The files can be linked by the variable RXDDRGID.
The file named RXQ_RX_E contains data on all survey participants and their use of a prescription drug. Participants who reported the use of multiple prescription drugs will have multiple records, that is, a record for each drug.
The file named RXQ_DRUG contains therapeutic drug class information on all drugs reported in NHANES. It contains drug (up to 4) and ingredient (up to 6) therapeutic category codes for each drug. It also has a variable that identifies if the drug is made up of a single or multiple ingredients.
Variable Name | Label |
---|---|
SEQN | Respondent sequence number |
RXDUSE | Taken prescription medicine, past month |
RXDDRUG | Generic drug name |
RXDDRGID | Generic drug code |
RXQSEEN | Medicine container seen by interviewer |
RXDDAYS | Number of days taken medicine |
RXDCOUNT | Number of prescription medicines taken |
Variable Name | Label |
---|---|
RXDDRGID | GENERIC DRUG CODE |
RXDDRUG | GENERIC DRUG NAME |
RXDINGFL | SINGLE/MULTIPLE INGREDIENT DRUG |
RXDDCI1A | DRUG CATEGORY ID - CATEGORY 1, LEVEL 1 |
RXDDCI1B | DRUG CATEGORY ID - CATEGORY 1, LEVEL 2 |
RXDDCI1C | DRUG CATEGORY ID - CATEGORY 1, LEVEL 3 |
RXDDCI2A | DRUG CATEGORY ID - CATEGORY 2, LEVEL 1 |
RXDDCI2B | DRUG CATEGORY ID - CATEGORY 2, LEVEL 2 |
RXDDCI2C | DRUG CATEGORY ID - CATEGORY 2, LEVEL 3 |
RXDDCI3A | DRUG CATEGORY ID - CATEGORY 3, LEVEL 1 |
RXDDCI3B | DRUG CATEGORY ID - CATEGORY 3, LEVEL 2 |
RXDDCI3C | DRUG CATEGORY ID - CATEGORY 3, LEVEL 3 |
RXDDCI4A | DRUG CATEGORY ID - CATEGORY 4, LEVEL 1 |
RXDDCI4B | DRUG CATEGORY ID - CATEGORY 4, LEVEL 2 |
RXDDCI4C | DRUG CATEGORY ID - CATEGORY 4, LEVEL 3 |
RXDDCN1A | DRUG CATEGORY NAME - CATEGORY 1, LEVEL 1 |
RXDDCN1B | DRUG CATEGORY NAME - CATEGORY 1, LEVEL 2 |
RXDDCN1C | DRUG CATEGORY NAME - CATEGORY 1, LEVEL 3 |
RXDDCN2A | DRUG CATEGORY NAME - CATEGORY 2, LEVEL 1 |
RXDDCN2B | DRUG CATEGORY NAME - CATEGORY 2, LEVEL 2 |
RXDDCN2C | DRUG CATEGORY NAME - CATEGORY 2, LEVEL 3 |
RXDDCN3A | DRUG CATEGORY NAME - CATEGORY 3, LEVEL 1 |
RXDDCN3B | DRUG CATEGORY NAME - CATEGORY 3, LEVEL 2 |
RXDDCN3C | DRUG CATEGORY NAME - CATEGORY 3, LEVEL 3 |
RXDDCN4A | DRUG CATEGORY NAME - CATEGORY 4, LEVEL 1 |
RXDDCN4B | DRUG CATEGORY NAME - CATEGORY 4, LEVEL 2 |
RXDDCN4C | DRUG CATEGORY NAME - CATEGORY 4, LEVEL 3 |
RXDICI1A | INGREDIENT CATEGORY ID - CATEGORY 1, LEVEL 1 |
RXDICI1B | INGREDIENT CATEGORY ID - CATEGORY 1, LEVEL 2 |
RXDICI1C | INGREDIENT CATEGORY ID - CATEGORY 1, LEVEL 3 |
RXDICI2A | INGREDIENT CATEGORY ID - CATEGORY 2, LEVEL 1 |
RXDICI2B | INGREDIENT CATEGORY ID - CATEGORY 2, LEVEL 2 |
RXDICI2C | INGREDIENT CATEGORY ID - CATEGORY 2, LEVEL 3 |
RXDICI3A | INGREDIENT CATEGORY ID - CATEGORY 3, LEVEL 1 |
RXDICI3B | INGREDIENT CATEGORY ID - CATEGORY 3, LEVEL 2 |
RXDICI3C | INGREDIENT CATEGORY ID - CATEGORY 3, LEVEL 3 |
RXDICI4A | INGREDIENT CATEGORY ID - CATEGORY 4, LEVEL 1 |
RXDICI4B | INGREDIENT CATEGORY ID - CATEGORY 4, LEVEL 2 |
RXDICI4C | INGREDIENT CATEGORY ID - CATEGORY 4, LEVEL 3 |
RXDICI5A | INGREDIENT CATEGORY ID - CATEGORY 5, LEVEL 1 |
RXDICI5B | INGREDIENT CATEGORY ID - CATEGORY 5, LEVEL 2 |
RXDICI5C | INGREDIENT CATEGORY ID - CATEGORY 5, LEVEL 3 |
RXDICI6A | INGREDIENT CATEGORY ID - CATEGORY 6, LEVEL 1 |
RXDICI6B | INGREDIENT CATEGORY ID - CATEGORY 6, LEVEL 2 |
RXDICI6C | INGREDIENT CATEGORY ID - CATEGORY 6, LEVEL 3 |
RXDICN1A | INGREDIENT CATEGORY NAME - CATEGORY 1, LEVEL 1 |
RXDICN1B | INGREDIENT CATEGORY NAME - CATEGORY 1, LEVEL 2 |
RXDICN1C | INGREDIENT CATEGORY NAME - CATEGORY 1, LEVEL 3 |
RXDICN2A | INGREDIENT CATEGORY NAME - CATEGORY 2, LEVEL 1 |
RXDICN2B | INGREDIENT CATEGORY NAME - CATEGORY 2, LEVEL 2 |
RXDICN2C | INGREDIENT CATEGORY NAME - CATEGORY 2, LEVEL 3 |
RXDICN3A | INGREDIENT CATEGORY NAME - CATEGORY 3, LEVEL 1 |
RXDICN3B | INGREDIENT CATEGORY NAME - CATEGORY 3, LEVEL 2 |
RXDICN3C | INGREDIENT CATEGORY NAME - CATEGORY 3, LEVEL 3 |
RXDICN4A | INGREDIENT CATEGORY NAME - CATEGORY 4, LEVEL 1 |
RXDICN4B | INGREDIENT CATEGORY NAME - CATEGORY 4, LEVEL 2 |
RXDICN4C | INGREDIENT CATEGORY NAME - CATEGORY 4, LEVEL 3 |
RXDICN5A | INGREDIENT CATEGORY NAME - CATEGORY 5, LEVEL 1 |
RXDICN5B | INGREDIENT CATEGORY NAME - CATEGORY 5, LEVEL 2 |
RXDICN5C | INGREDIENT CATEGORY NAME - CATEGORY 5, LEVEL 3 |
RXDICN6A | INGREDIENT CATEGORY NAME - CATEGORY 6, LEVEL 1 |
RXDICN6B | INGREDIENT CATEGORY NAME - CATEGORY 6, LEVEL 2 |
RXDICN6C | INGREDIENT CATEGORY NAME - CATEGORY 6, LEVEL 3 |
The variable RXDCOUNT provides a count of all prescription products reported in the prescription medication section, adjusting for products moved into or out of the final file. The count includes products reported as “refused” or “don’t know” by participants who reported they had taken a prescription medication but did not know the name of the medication or refused to report the name of the medication. Drugs released as “unknown drug” are also included in the count. However, prescription supplements in the Dietary Supplements File are not included in the total count. Therefore, this variable does not provide a comprehensive count of all prescription products used by the survey participants.
In some cases it may appear as though respondents reported the same prescription drug more than once. That is, the same generic ingredient name and product code may be listed more than once. There are a several reasons for these duplications. Respondents may have reported different brand name medications which had the same generic ingredient name (e.g., “Adalat” vs. “Procardia”), the medications may have been different forms or dosages of the same product, or the participant may have reported different lengths of use or reasons for use of the products. There were a few cases where the respondent did report the exact same drug more than once, with the same length of use, and reason for use. In these cases, since the interviewer recorded that a separate medication container was seen for each reported drug, both mentions of the drug were retained in the file.
During the data editing process, outlier values were examined. When there was insufficient information to conclude that values were invalid, they were left in the data set. Analysts should examine the distribution of the data and consider whether or not it is appropriate to include or exclude extreme values in a given analysis
Please refer to the NHANES Analytic Guidelines and the on-line NHANES Tutorial for further details on the use of sample weights and other analytic issues. Both of these are available on the NHANES website.
Code or Value | Value Description | Count | Cumulative | Skip to Item |
---|---|---|---|---|
1 | Yes | 14759 | 14759 | |
2 | No | 5751 | 20510 | End of Section |
7 | Refused | 2 | 20512 | End of Section |
9 | Don't know | 4 | 20516 | End of Section |
. | Missing | 0 | 20516 |
Code or Value | Value Description | Count | Cumulative | Skip to Item |
---|---|---|---|---|
Generic drug name | Value was recorded | 14699 | 14699 | |
55555 | Unknown | 7 | 14706 | |
77777 | Refused | 8 | 14714 | |
99999 | Don't know | 45 | 14759 | |
< blank > | Missing | 5757 | 20516 |
Code or Value | Value Description | Count | Cumulative | Skip to Item |
---|---|---|---|---|
Generic drug code | Value was recorded | 14699 | 14699 | |
< blank > | Missing | 5817 | 20516 |
Code or Value | Value Description | Count | Cumulative | Skip to Item |
---|---|---|---|---|
1 | Yes | 12353 | 12353 | |
2 | No | 2300 | 14653 | |
. | Missing | 5863 | 20516 |
Code or Value | Value Description | Count | Cumulative | Skip to Item |
---|---|---|---|---|
1 to 24455 | Range of Values | 14464 | 14464 | |
77777 | Refused | 0 | 14464 | |
99999 | Don't know | 231 | 14695 | |
. | Missing | 5821 | 20516 |
Code or Value | Value Description | Count | Cumulative | Skip to Item |
---|---|---|---|---|
1 to 18 | Range of Values | 14759 | 14759 | |
. | Missing | 5757 | 20516 |